Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
RESEARCH TOOLSreports
Holding OLMA?
Track your performance easily
OLMA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.12 - $16.78
Previous Close$8.28
Volume1.23M
Average Volume (3M)465.51K
Market Cap
$499.64M
Enterprise Value$286.57M
Total Cash (Recent Filing)$214.76M
Total Debt (Recent Filing)$1.70M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Mar 03, 2025EPS Estimate
-$0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.19
Shares Outstanding57,297,845
10 Day Avg. Volume528,973
30 Day Avg. Volume465,506
Standard Deviation0.28
R-Squared0.11
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)2.39
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.29
Forecast
1Y Price Target
$28.50Price Target Upside262.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Olema Pharmaceuticals News
PremiumCompany Announcements
Olema Pharmaceuticals Advances Breast Cancer Treatment Trials
Bulls Say, Bears Say
Bulls Say
Clinical Trials And Drug DevelopmentThe combination of palazestrant and ribociclib is advancing into a Phase 3 study, suggesting promising progress in clinical trials.
Market Position And Competitive AdvantageThe collaboration and expansion with Novartis could enhance Olema's positioning in the market for ER+ breast cancer treatments.
Partnerships And CollaborationsThe expanded clinical collaboration and supply agreement with Novartis reflects confidence in the potential of palazestrant + ribociclib for advanced ER+ breast cancer treatment.
Bears Say
Cash FlowOlema has an annualized cash burn of $108 million.
Market SentimentThe short interest in Olema's stock is relatively high, at 17.2% of the float.
Safety ConcernsThe most frequent Grade 3 or higher treatment-related adverse event was neutropenia.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
OLMA FAQ
What was Olema Pharmaceuticals’s price range in the past 12 months?
Olema Pharmaceuticals lowest stock price was $8.12 and its highest was $16.77 in the past 12 months.
What is Olema Pharmaceuticals’s market cap?
Currently, no data Available
When is Olema Pharmaceuticals’s upcoming earnings report date?
Olema Pharmaceuticals’s upcoming earnings report date is Mar 03, 2025 which is in 100 days.
How were Olema Pharmaceuticals’s earnings last quarter?
Olema Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.571 by -$0.029.
Is Olema Pharmaceuticals overvalued?
According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued.
Does Olema Pharmaceuticals pay dividends?
Olema Pharmaceuticals does not currently pay dividends.
What is Olema Pharmaceuticals’s EPS estimate?
Olema Pharmaceuticals’s EPS estimate is -$0.65.
How many shares outstanding does Olema Pharmaceuticals have?
Olema Pharmaceuticals has 57,297,844 shares outstanding.
What happened to Olema Pharmaceuticals’s price movement after its last earnings report?
Olema Pharmaceuticals reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.571. Following the earnings report the stock price went down -0.52%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals?
Among the largest hedge funds holding Olema Pharmaceuticals’s share is Woodline Partners LP. It holds Olema Pharmaceuticals’s shares valued at 16M.
---
Olema Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.50 (262.13% Upside)
$28.50 (262.13% Upside)
Hedge Fund Trend
Increased
By 550.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.08%
12-Months-Change
Fundamentals
Return on Equity
-51.76%
Trailing 12-Months
Asset Growth
-21.39%
Trailing 12-Months
Company Description
Olema Pharmaceuticals
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250.
---
OLMA Stock 12 Month Forecast
Average Price Target
$28.50
▲(262.13% Upside)
Technical Analysis
Best Analysts Covering OLMA
1 Year
1 Year Success Rate
8/18 ratings generated profit
1 Year Average Return
+74.31%
reiterated a buy rating 10 days ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +74.31% per trade.
---